Table 2

Survival of chronic obstructive pulmonary disease patients receiving fluticasone propionate (FP) and/or salmeterol and reference patients#

FP and/or salmeterolReference
Total n10453620
Survival %
 Year 196.2*88.4
 Year 289.4*75.0
 Year 378.6*63.6
Females n5401600
Survival %
 Year 196.0*88.6
 Year 289.3*76.2
 Year 380.4*65.6
Males n5052020
Survival %
 Year 196.4*88.3
 Year 289.5*74.0
 Year 376.4*62.0
Age at diagnosis n (% 3 yr survival)
 50–59 yrs225 (91.5)367 (90.7)
 60–69 yrs397 (87.4)*931 (75.0)
 70–79 yrs328 (68.9)*1362 (62.2)
 ≥80 yrs95 (46.5)960 (45.7)
Mention of asthma n (% 3 yr survival)
 Yes777 (79.5)*1009 (63.1)
 No268 (75.4)*2611 (63.8)
  • #: Kaplan-Meier estimates of survival per 100 patients

  • *: p<0.05 versus reference group